Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
JACC Clin Electrophysiol. 2020 Dec;6(14):1773-1782. doi: 10.1016/j.jacep.2020.07.004. Epub 2020 Sep 16.
This study sought to evaluate the safety and feasibility of conduction system pacing by performing left bundle branch area pacing (LBBAP).
There are limited data from single centers showing that LBBAP may circumvent the technical and electrophysiological challenges encountered with His bundle pacing.
Patients referred for pacemaker implantation at 2 centers between February 1, 2019, and March 31, 2020, were considered for LBBAP. LBBAP was performed by implanting a lumen-less, exposed helix lead approximately 2 cm distal to the His bundle and deep into the septum using a specialized delivery sheath. Implant success rates, complications, and electrophysiological parameters were assessed.
LBBAP was successful in 305 of 341 patients (89%). Mean age was 72 ± 12 years; 45% were women; and 39% had QRS duration (QRSd) >130 ms, 22% right bundle branch block, 11% left bundle branch block, and 6% intraventricular conduction defect. Pacing indications were sinus node dysfunction in 28.7%, atrioventricular block in 52.5%, cardiac resynchronization therapy in 8.8%, and refractory atrial fibrillation in 10% of patients. Procedural duration was 74.7 ± 34 min and fluoroscopic time was 10.4 ± 8.1 min. The mean baseline QRSd and paced QRSd in the overall cohort was 114 ± 29.8 ms versus 112 ± 11.7 ms (p < 0.001) and in patients with infra-Hisian disease was 144.5 ± 19 ms versus 115 ± 12 ms (p < 0.001), respectively. Mean left ventricular activation time was 71.7 ± 11 ms at high output and 74.7 ± 11 ms at low output. LBB potentials were noted in 41% patients. Pacing threshold and R waves were 0.74 ± 0.3 V at 0.4 ms and 10.7 ± 4.9 mV at time of implantation and were stable at 1-, 3-, 6-, and 12-month follow-ups. The only major complications were 3 LBBAP lead dislodgements, 2 within 24 h and 1 at 2 weeks.
LBBA pacing is safe, feasible, and a reliable alternative to His bundle pacing for providing physiological pacing. Randomized controlled studies are needed to confirm the safety, feasibility, and clinical outcomes of LBBAP.
本研究旨在评估通过行左束支区域起搏(LBBAP)进行传导系统起搏的安全性和可行性。
仅有少数来自单中心的数据表明,LBBAP 可能规避希氏束起搏所遇到的技术和电生理挑战。
2019 年 2 月 1 日至 2020 年 3 月 31 日期间,在 2 个中心就诊并拟植入起搏器的患者被考虑行 LBBAP。通过使用专门的输送鞘将无腔、暴露的螺旋导联植入希氏束远端约 2cm 并深入间隔,从而进行 LBBAP。评估植入成功率、并发症和电生理参数。
在 341 例患者中,305 例(89%)LBBAP 成功。平均年龄为 72±12 岁;45%为女性;39%的患者 QRS 时限(QRSd)>130ms,22%存在右束支阻滞,11%存在左束支阻滞,6%存在室内传导障碍。起搏适应证分别为窦性心动过缓 28.7%,房室传导阻滞 52.5%,心脏再同步治疗 8.8%,以及难治性心房颤动 10%。手术时间为 74.7±34min,透视时间为 10.4±8.1min。总体队列的平均基线 QRSd 和起搏 QRSd 分别为 114±29.8ms 比 112±11.7ms(p<0.001)和希氏下疾病患者分别为 144.5±19ms 比 115±12ms(p<0.001)。左心室激活时间平均为高输出时 71.7±11ms 和低输出时 74.7±11ms。41%的患者记录到左束支电位。起搏阈值和 R 波分别在植入时为 0.74±0.3V 和 10.7±4.9mV,在 1、3、6 和 12 个月随访时稳定。唯一的主要并发症是 3 例 LBBAP 导联脱位,其中 2 例发生在 24 小时内,1 例发生在 2 周时。
LBBA 起搏是一种安全、可行的方法,是为提供生理性起搏而替代希氏束起搏的可靠选择。需要进行随机对照研究来证实 LBBAP 的安全性、可行性和临床结果。